Efficacy and safety of pegylated interferon in the treatment of JAK2V617F-positive polycythemia vera with a dose de-escalation strategy: a single-center retrospective study
The study found that initiating PEG-IFN at 180ug weekly and adjusting only for adverse events was well-tolerated and may offer superior outcomes to traditional dosing strategies. The 12-month hematological and molecular efficacy were promising, suggesting this approach has the potential to improve long-term survival in PV patients, although further research is needed to confirm these findings.
Authors
- Minghui Duan (ORCID: https://orcid.org/0000-0003-2130-6300)
- Hao Cai (ORCID: https://orcid.org/0000-0003-2153-9470)
- Wenxin Li (ORCID: https://orcid.org/0000-0001-6660-477X)
- Jian Li (ORCID: https://orcid.org/0000-0002-4549-0694)
- Long Chang (ORCID: https://orcid.org/0000-0002-1026-016X)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-05-14
- DOI
- https://doi.org/10.3389/fonc.2025.1586839
- Citations
- 1
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.63